CG Oncology, Inc. Common stock (CGON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CG Oncology, Inc. Common stock (CGON) has a cash flow conversion efficiency ratio of -0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-36.22 Million) by net assets ($752.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CGON market cap for the company's overall valuation and market capitalisation.
CG Oncology, Inc. Common stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how CG Oncology, Inc. Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CG Oncology, Inc. Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CG Oncology, Inc. Common stock ranked by their cash flow conversion efficiency. See CG Oncology, Inc. Common stock (CGON) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Amneal Pharmaceuticals, Inc. Class A Common Stock
NASDAQ:AMRX
|
-0.165x |
|
JBTMarel Corp
NYSE:JBTM
|
0.027x |
|
Westports Holdings Bhd
KLSE:5246
|
0.083x |
|
NEXGEN ENERGY LTD CDI/1
F:6NEA
|
-0.005x |
|
Wuxi Taiji Industry Co Ltd
SHG:600667
|
0.015x |
|
Coca-Cola FEMSA S.A.B. de C.V
MX:KOFUBL
|
0.072x |
|
RTL Group SA
XETRA:RRTL
|
0.009x |
|
Capital Financial Indonesia Tbk PT
JK:CASA
|
-0.145x |
Annual Cash Flow Conversion Efficiency for CG Oncology, Inc. Common stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of CG Oncology, Inc. Common stock from 2021 to 2025. View CG Oncology, Inc. Common stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $752.60 Million | $-132.35 Million | -0.176x | -63.84% |
| 2024-12-31 | $733.38 Million | $-78.71 Million | -0.107x | +56.58% |
| 2023-12-31 | $184.79 Million | $-45.68 Million | -0.247x | -3.82% |
| 2022-12-31 | $125.18 Million | $-29.80 Million | -0.238x | +29.81% |
| 2021-12-31 | $40.25 Million | $-13.65 Million | -0.339x | -- |
About CG Oncology, Inc. Common stock
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinic… Read more